A Case of Embolism of Left Posterior Tibial Artery after Successful Pregnancy and Delivery in a Patient with a Mechanical Valve Replacement Using Subcutaneous Injection of Low Molecular Weight Heparin

2002 ◽  
Vol 10 (1) ◽  
pp. 96
Author(s):  
Deok Won Bang ◽  
Sang Cheol Lee ◽  
Dae Hee Han ◽  
Ho Seok Jung ◽  
Eui Ryong Jung ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Subcutaneous Injection ◽  
Low Molecular Weight Heparin ◽  
Mechanical Valve ◽  
Posterior Tibial Artery ◽  
Low Molecular Weight ◽  
Successful Pregnancy ◽  
Posterior Tibial ◽  
Left Posterior ◽  
Pregnancy And Delivery

scholarly journals Thromboembolism and antithrombotic management in pregnancy

2011 ◽  
Vol 152 (21) ◽  
pp. 815-821 ◽  
Author(s):  
Attila Pajor
Keyword(s):  
Risk Factors ◽  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Individual Risk ◽  
Low Molecular Weight ◽  
Pregnancy And Delivery ◽  
Individual Risk Factors ◽  
In Pregnancy

Venous thromboembolism occurs approximately in 1 of 1000 pregnancies. It is one of the leading causes of maternal mortality. Physiologic changes associated with pregnancy and delivery favor for developing venous thromboembolism, and there are individual risk factors, too, contributing to its manifestation. The most frequent risk factors of venous thromboembolism developing during pregnancy are the previous venous thromboembolism and the thrombophilias, furthermore, some other diseases and some unique complications of pregnancy and delivery. Beyond mechanical prevention only heparin preparations can be used for preventing and treating venous thromboembolism in pregnancy and among them the low-molecular-weight heparins are preferred for applying. Dosage of low-molecular-weight heparin preparations is determined by the type and strength of thrombophilia. For treatment of venous thromboembolism presented during pregnancy subcutaneous 100 IU/kg low-molecular-weight heparin is generally used at every 12 hours. Postpartum the oral anticoagulants can be safely applied, too. Orv. Hetil., 2011, 152, 815–821.

scholarly journals Thromboprophylaxis implementation during pregnancy in women with recurrent foetal losses and thrombophilia

2011 ◽  
Vol 64 (9-10) ◽  
pp. 471-475 ◽  
Author(s):  
Gorana Mitic ◽  
Aleksandra Novakov-Mikic ◽  
Ljubica Povazan ◽  
Anita Mitreski ◽  
Vesna Kopitovic ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Pregnancy Outcome ◽  
Antiphospholipid Syndrome ◽  
Low Molecular Weight Heparin ◽  
Clinical Problem ◽  
Low Molecular Weight ◽  
Primary Antiphospholipid Syndrome ◽  
Successful Pregnancy ◽  
Foetal Loss ◽  
Reproductive Females

Recurrent foetal loss is a significant clinical problem, occurring in 1-5% of reproductive females. Inherited or acquired thrombophilia has been diagnosed in 50-65% of women with history of unexplained foetal loss. The low molecular weight heparin was applied in 24 women with inherited thrombophilia and previous recurrent foetal loss and in 6 women with primary antiphospholipid syndrome throughout their following pregnancies. The dose of low molecular weight heparin for the majority of women was 35-75 u/kg. Women with primary antiphospholipid syndrome received both low molecular weight heparin and aspirin 50-100 mg daily. Implementation of thromboprophylaxis resulted in successful pregnancy outcome in 29 out of 38 pregnancies, which represents a significant improvement of pregnancy outcome in comparison to previous 81 pregnancy losses. The number of treated pregnancies in our study is small, but the rate of successful pregnancy outcomes is high (76%), indicating that low molecular weight heparin may be a promising approach to women with thrombophilia and recurrent foetal loss.

Sign in / Sign up

Export Citation Format

Share Document